Reduced-Dose Post-Transplantation Cyclophosphamide (PTCy) Facilitates Faster T-cell Recovery with Clinical Implications for Engraftment, Chronic GVHD, and Non-Relapse Mortality

Key Points

• Faster T-cell recovery is observed with reduced-dose post-transplantation cyclophosphamide treatment, leading to improved outcomes.
• Notably, 30% faster immune reconstitution was recorded, contributing to better patient survivability.
• The observational analysis focused on patients receiving reduced-dose cyclophosphamide after hematopoietic stem cell transplantation.
• This approach may reduce risks of chronic GVHD and non-relapse mortality in transplant patients.